Metraipolis › archive › dc_0f828836b7bc

Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis — Europe PMC PMID:41025752

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41025752
DOI
10.1111/ddg.15897
License (as archived)
solo-consultazione
Archived
2026-11-09T15:19:22.198Z
SHA-256 of the archived text
b54b83c4b2de0a927d56908f1f0a3230def3742e7ea868b52340861622855dfb
Stable URL of this page
https://metraipolis.com/documento/dc_0f828836b7bc

How to cite

Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis — Europe PMC PMID:41025752 — Europe PMC (en), https://europepmc.org/article/MED/41025752 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0f828836b7bc (Metraipolis archive dc_0f828836b7bc, sha256 b54b83c4b2de0a927d56908f1f0a3230def3742e7ea868b52340861622855dfb)
BibTeX
@misc{dc0f828836b7bc,
  title = {Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis — Europe PMC PMID:41025752},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41025752},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0f828836b7bc; sha256 b54b83c4b2de0a927d56908f1f0a3230def3742e7ea868b52340861622855dfb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41025752. Agents can read the archived copy with the MCP tool read_document.